JP4709774B2 - 抗炎症活性を有するマクロライド - Google Patents

抗炎症活性を有するマクロライド Download PDF

Info

Publication number
JP4709774B2
JP4709774B2 JP2006550180A JP2006550180A JP4709774B2 JP 4709774 B2 JP4709774 B2 JP 4709774B2 JP 2006550180 A JP2006550180 A JP 2006550180A JP 2006550180 A JP2006550180 A JP 2006550180A JP 4709774 B2 JP4709774 B2 JP 4709774B2
Authority
JP
Japan
Prior art keywords
group
alkyl group
hydrogen atom
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006550180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007519685A5 (cg-RX-API-DMAC7.html
JP2007519685A (ja
Inventor
メレウ,アンドレア
ナポレターノ,マウロ
オルナーギ,フェルナンド
モリッジ,エルマンノ
ペラッチーニ,フランコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zambon Group SpA
Original Assignee
Zambon Group SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Group SpA filed Critical Zambon Group SpA
Publication of JP2007519685A publication Critical patent/JP2007519685A/ja
Publication of JP2007519685A5 publication Critical patent/JP2007519685A5/ja
Application granted granted Critical
Publication of JP4709774B2 publication Critical patent/JP4709774B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2006550180A 2004-01-29 2005-01-25 抗炎症活性を有するマクロライド Expired - Fee Related JP4709774B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2004A000124 2004-01-29
IT000124A ITMI20040124A1 (it) 2004-01-29 2004-01-29 Macrolidi ad attivita' antiinfiammatoria
PCT/EP2005/050312 WO2005075494A1 (en) 2004-01-29 2005-01-25 Macrolides with antiinflammatory activity

Publications (3)

Publication Number Publication Date
JP2007519685A JP2007519685A (ja) 2007-07-19
JP2007519685A5 JP2007519685A5 (cg-RX-API-DMAC7.html) 2011-04-07
JP4709774B2 true JP4709774B2 (ja) 2011-06-22

Family

ID=34835570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006550180A Expired - Fee Related JP4709774B2 (ja) 2004-01-29 2005-01-25 抗炎症活性を有するマクロライド

Country Status (10)

Country Link
US (1) US7507721B2 (cg-RX-API-DMAC7.html)
EP (1) EP1713818A1 (cg-RX-API-DMAC7.html)
JP (1) JP4709774B2 (cg-RX-API-DMAC7.html)
CN (1) CN1956993B (cg-RX-API-DMAC7.html)
AU (1) AU2005210032B9 (cg-RX-API-DMAC7.html)
CA (1) CA2554070C (cg-RX-API-DMAC7.html)
EA (1) EA010906B1 (cg-RX-API-DMAC7.html)
IL (1) IL176846A (cg-RX-API-DMAC7.html)
IT (1) ITMI20040124A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005075494A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102988120B1 (ko) * 2020-03-12 2026-07-09 조에티스 서비시즈 엘엘씨 면역조절성 유레아 아잘라이드

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091196B2 (en) 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
EP2716647A3 (en) 2004-02-27 2014-08-20 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
US20080249034A1 (en) * 2005-03-21 2008-10-09 Zambon S.P.A. Use of Macrolides for Treating Intestinal Inflammation
JP5126685B2 (ja) 2006-05-01 2013-01-23 大正製薬株式会社 マクロライド誘導体
PL2102226T3 (pl) * 2006-12-12 2013-01-31 Zambon Spa Związki makrolidowe o aktywności przeciwzapalnej
AU2022343476B2 (en) * 2021-09-07 2025-02-20 Zoetis Services Llc Immunomodulating azalides
WO2024194494A1 (en) * 2023-03-22 2024-09-26 Epiendo Pharmaceuticals Ehf Azithromycin derivatives for use in the treatment of eosinophil-related diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215980A (en) * 1992-01-17 1993-06-01 Merck & Co., Inc. 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof
IT1306205B1 (it) * 1999-01-15 2001-05-30 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
ITMI20021726A1 (it) * 2002-08-01 2004-02-02 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102988120B1 (ko) * 2020-03-12 2026-07-09 조에티스 서비시즈 엘엘씨 면역조절성 유레아 아잘라이드

Also Published As

Publication number Publication date
EA010906B1 (ru) 2008-12-30
AU2005210032B9 (en) 2011-06-09
CN1956993A (zh) 2007-05-02
EP1713818A1 (en) 2006-10-25
AU2005210032B2 (en) 2011-01-20
IL176846A0 (en) 2006-10-31
WO2005075494A1 (en) 2005-08-18
CA2554070C (en) 2011-10-11
US20070167381A1 (en) 2007-07-19
EA200601368A1 (ru) 2007-02-27
US7507721B2 (en) 2009-03-24
JP2007519685A (ja) 2007-07-19
AU2005210032A1 (en) 2005-08-18
IL176846A (en) 2011-01-31
CN1956993B (zh) 2012-10-31
ITMI20040124A1 (it) 2004-04-29
CA2554070A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
RU2330856C2 (ru) Макролидные соединения, обладающие противовоспалительной активностью
JPH053476B2 (cg-RX-API-DMAC7.html)
RU2320668C2 (ru) 9а-азалиды с противовоспалительной активностью
JP2007519685A (ja) 抗炎症活性を有するマクロライド
AU769514B2 (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments
JP2008519787A (ja) マクロロン化合物
CN101558078B (zh) 具有抗炎活性的大环内酯化合物
JP2001523684A (ja) エリスロマイシン類および該化合物の誘導体のn−脱メチル化方法
CN1318441C (zh) 大环内酯类抗生素的酮内酯化合物及其制备方法和用途
JP2007223900A (ja) 6−o−置換ケトライド誘導体
MXPA01010624A (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments
JP2004331632A (ja) 2−フルオロ−6−o−置換ケトライド誘導体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20110105

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110221

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110318

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees